Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VITALITY BIOPHARMA, INC.

(VBIO)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vitality Biopharma : Letter from Weinberg and Co., P.A. to the Securities and Exchange Commission (Form 8-K)

06/16/2021 | 04:08pm EDT

Exhibit 16.1

June 16, 2021

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7561

Dear Sirs/Madams:

We have read Item 4.01 of Vitality Biopharma Inc.'s Form 8-K dated June 16, 2021, and agree with the statements made in Item 4.01(a). We have no basis to agree or disagree with other statements of the registrant contained therein.

Yours truly,

/s/ Weinberg & Company, P.A.

Los Angeles, California

Disclaimer

Vitality Biopharma Inc. published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 20:07:10 UTC.


ę Publicnow 2021
All news about VITALITY BIOPHARMA, INC.
09/02Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility
GL
09/02VITALITY BIOPHARMA : ANNOUNCES EFFECTIVE S-1 REGISTRATION STATEMENT AND DTC ELIGIBILITY (F..
PU
09/02VITALITY BIOPHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/23VITALITY BIOPHARMA : Enters into $5 million equity financing relationship with institution..
AQ
08/20VITALITY BIOPHARMA : ENTERS INTO $5 MILLION EQUITY LINE FINANCING RELATIONSHIP WITH INSTIT..
PU
08/20VITALITY BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Other Events, Finan..
AQ
08/20Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Insti..
GL
08/19Vitality Biopharma, Inc. announced that it expects to receive $5 million in funding
CI
08/13VITALITY BIOPHARMA : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/13Vitality Biopharma, Inc. Reports Earnings Results for the First Quarter Ended June 30, ..
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -0,88 M - -
Net cash 2021 0,85 M - -
P/E ratio 2021 -10,4x
Yield 2021 -
Capitalization 16,9 M 16,9 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 3
Free-Float 66,4%
Chart VITALITY BIOPHARMA, INC.
Duration : Period :
Vitality Biopharma, Inc. Technical Analysis Chart | VBIO | US92849B1070 | MarketScreener
Income Statement Evolution
Managers and Directors
Michael Cavanaugh Chief Executive Officer & Director
Richard McKilligan Controller, Chief Financial & Accounting Officer
Edward F. Feighan Executive Chairman
Brandon Zipp Chief Science Officer
Richard F. Celeste Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VITALITY BIOPHARMA, INC.450.00%19
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634